OFF-LABEL USE OF SECOND-GENERATION ANTIPSYCHOTICS

被引:0
|
作者
Spina, Edoardo [1 ,2 ]
Fava, Giuseppina [1 ]
Makos, Xenofon [1 ]
机构
[1] Univ Messina, Dept Clin & Expt Med & Pharmacol, Pharmacol Sect, Policlinico Univ,Via Consolare, I-98125 Messina, Italy
[2] IRCCS, Ctr Neurolesi BoninoPulejo, Messina, Italy
来源
CLINICAL NEUROPSYCHIATRY | 2009年 / 6卷 / 01期
关键词
Antipsychotics; Off label; Bipolar depression; Behavioral and psychological symptoms of dementia; Obsessive-compulsive disorder; Borderline personality disorder; Dopaminergic psychosis; Generalized anxiety disorder;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
All second-generation antipsychotics are licensed for the treatment of schizophrenia. Some of these agents are also approved for the treatment of acute mania and for maintenance therapy of bipolar disorder. In view of a broader spectrum of activity and a more favourable tolerability profile as compared to first-generation compounds, second generation antipsychotics are increasingly used oil-label for the treatment of many psychiatric conditions, either as monotherapy, or as an augmentation strategy. This article reviews the available data concerning the use of second generation antipsychotics in the most common off-label indications in adult and elderly psychiatric patients, such as bipolar depression, behavioural and psychological symptoms of dementia, obsessive-compulsive disorder, borderline personality disorder, dopaminergic psychosis and generalized anxiety disorder.
引用
收藏
页码:11 / 20
页数:10
相关论文
共 50 条
  • [31] Off-Label Use of Antipsychotics and Health Related Quality of Life in Community Living Older Adults
    Hamzah Bakouni
    Helen-Maria Vasiliadis
    Applied Research in Quality of Life, 2020, 15 : 991 - 1004
  • [32] Off-label use of contrast agents
    Reimer, P.
    Vosshenrich, R.
    EUROPEAN RADIOLOGY, 2008, 18 (06) : 1096 - 1101
  • [33] Registered and off-label use of psychotropics
    Jandl, Martin
    Baumhauer-Gessler, Helga
    Kaschka, Wolfgang P.
    Steinert, Tilman
    PSYCHOPHARMAKOTHERAPIE, 2011, 18 (05): : 220 - 226
  • [34] Off-Label Use of the WEB Device
    Zanaty, Mario
    Roa, Jorge A.
    Tjoumakaris, Stavropoula, I
    Jabbour, Pascal
    Mouchtouris, Nikolaos
    Sweid, Ahmad
    Ortega-Gutierrez, Santiago
    Ishii, Daizo
    Limaye, Kaustubh
    Asi, Khaled
    Samaniego, Edgar A.
    Hasan, David M.
    WORLD NEUROSURGERY, 2020, 134 : E1047 - E1052
  • [35] Off-label use of contrast agents
    P. Reimer
    R. Vosshenrich
    European Radiology, 2008, 18 : 1096 - 1101
  • [36] Use of pharmaceuticals 'Off-Label' in the neonate
    Tobin, Joseph R.
    BEST PRACTICE & RESEARCH-CLINICAL ANAESTHESIOLOGY, 2010, 24 (03) : 451 - 460
  • [37] Second-generation antipsychotics and metabolic syndrome: a role for mitochondria
    Mortimer, Katherine R. H.
    Katshu, Mohammed Zia Ul Haq
    Chakrabarti, Lisa
    FRONTIERS IN PSYCHIATRY, 2023, 14
  • [38] Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trial
    Sen, Hanim
    Lam, Ming Kai
    Tandjung, Kenneth
    Basalus, Mounir W. Z.
    de Man, Frits H. A. F.
    Louwerenburg, J. Hans W.
    Stoel, Martin G.
    van Houwelingen, Gert K.
    Lowik, Marije M.
    Linssen, Gerard C. M.
    Said, Salah A. M.
    Nienhuis, Mark B.
    Verhorst, Patrick M. J.
    van der Palen, Job
    von Birgelen, Clemens
    EUROINTERVENTION, 2014, 10 (06) : 664 - 671
  • [39] Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia
    Caruso, Giuseppe
    Grasso, Margherita
    Fidilio, Annamaria
    Tascedda, Fabio
    Drago, Filippo
    Caraci, Filippo
    PHARMACEUTICALS, 2020, 13 (12) : 1 - 20
  • [40] Metabolic Monitoring of Patients Prescribed Second-Generation Antipsychotics
    Dhamane, Amol D.
    Martin, Bradley C.
    Brixner, Diana I.
    Hudson, Teresa J.
    Said, Qayyim
    JOURNAL OF PSYCHIATRIC PRACTICE, 2013, 19 (05) : 360 - 374